DAGCO Inc’s Acadia Pharmaceuticals ACAD Stock Holding History

DAGCO Inc’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-131	Closed	-$4.1K	–	222
2023 Q4	$4.1K	Buy	+131	New	+$3.13K	﹤0.01%	228

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

DAGCO Inc's ACAD Position: Q1 2024 in Review

DAGCO Inc sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 131 shares — an estimated $4.1K sold.

DAGCO Inc first reported a position in ACAD in Q4 2023 and held it in 1 quarter. The position peaked at $4.1K in Q4 2023. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

DAGCO Inc reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
DAGCO Inc sold 131 Acadia Pharmaceuticals shares in Q1 2024, an estimated $4.1K.
DAGCO Inc first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
DAGCO Inc's Acadia Pharmaceuticals position peaked at $4.1K in Q4 2023.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on DAGCO Inc's 13F filing for Q1 2024, filed 15 May 2024.